Hospital
Valley Hospital Medical Center
Valley Hospital Medical Center was paid $47.03M by Medicaid between Jan 2018 and Dec 2024, across 324 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoVALLEY HOSPITAL MEDICAL CENTER
LAS VEGAS, NV 89106
LAS VEGAS, NV 89106
33aNPI1417947490assigned 10/21/2005
33bProvider typePsychiatric Hospital Unit
28Total paid$47.03M
24GClaims2,321,441
24DCodes billed324
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 187,723 | $2.72M | |
| 2019 | 398,862 | $7.41M | |
| 2020 | 350,669 | $6.51M | |
| 2021 | 377,144 | $7.32M | |
| 2022 | 321,810 | $7.19M | |
| 2023 | 364,312 | $8.05M | |
| 2024incomplete | 320,921 | $7.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 82,161 | 66,387 | $8.97M |
| G0378 | Hospital observation service, per hour | 11% | 44,823 | 29,830 | $4.96M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.6% | 38,581 | 34,012 | $3.58M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 12,603 | 10,565 | $3.20M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.6% | 20,537 | 17,384 | $2.17M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.8% | 34,431 | 28,255 | $1.81M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.6% | 8,568 | 7,268 | $1.69M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.8% | 2,722 | 2,321 | $1.34M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.7% | 4,572 | 3,844 | $1.27M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 51,198 | 39,932 | $1.13M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 45,300 | 32,858 | $1.05M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 56,110 | 43,610 | $882K |
312 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 53,837 | $865K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 4,477 | $683K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 4,763 | $634K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 10,878 | $508K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 17,684 | $477K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 38,958 | $459K |
| 96376 | <1% | 28,272 | $374K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 11,888 | $353K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 130,944 | $353K |
| 72131 | <1% | 2,075 | $314K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 68,583 | $304K |
| 80053 | Comprehensive metabolic panel | <1% | 71,188 | $298K |
| 84484 | <1% | 70,656 | $288K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 21,148 | $257K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,594 | $257K |
| 70496 | <1% | 847 | $254K | |
| 71045 | Radiologic examination, chest; single view | <1% | 47,192 | $253K |
| 11045 | <1% | 1,514 | $252K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 8,667 | $239K |
| 0450 | Emergency room services | <1% | 5,248 | $235K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 6,974 | $234K |
| 70498 | <1% | 829 | $231K | |
| 95819 | <1% | 1,422 | $203K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,267 | $200K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,712 | $199K |
| 36415 | Collection of venous blood by venipuncture | <1% | 154,698 | $199K |
| 97162 | <1% | 6,398 | $194K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 946 | $179K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 48,266 | $168K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,292 | $166K |
| 93970 | <1% | 2,957 | $155K | |
| 84702 | <1% | 25,776 | $151K | |
| 70486 | <1% | 1,432 | $150K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,657 | $149K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 11,195 | $144K |
| 76830 | Ultrasound, transvaginal | <1% | 1,935 | $134K |
| 83880 | <1% | 13,697 | $128K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,912 | $127K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 9,139 | $124K |
| 93971 | <1% | 3,087 | $119K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 453 | $115K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,132 | $115K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 35,692 | $93K |
| 83605 | <1% | 25,305 | $93K | |
| 83690 | <1% | 34,230 | $91K | |
| 71250 | <1% | 896 | $89K | |
| 83735 | <1% | 46,372 | $81K | |
| 97166 | <1% | 2,638 | $81K | |
| 76801 | <1% | 1,280 | $76K | |
| 90715 | <1% | 2,192 | $73K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,963 | $68K |
| 87040 | <1% | 16,056 | $65K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,007 | $64K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,206 | $61K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,034 | $57K |
| 81001 | <1% | 45,702 | $52K | |
| 73564 | <1% | 3,034 | $50K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 295 | $50K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 2,196 | $50K |
| 85730 | <1% | 30,766 | $50K | |
| 87641 | <1% | 7,640 | $50K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 5,541 | $49K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,140 | $49K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 289 | $49K |
| 96367 | <1% | 3,929 | $45K | |
| 93017 | <1% | 2,713 | $43K | |
| 82550 | <1% | 19,190 | $43K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,561 | $43K |
| 85610 | <1% | 36,170 | $40K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,516 | $39K |
| 97161 | <1% | 1,305 | $39K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,544 | $39K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,502 | $39K |
| 97116 | <1% | 4,590 | $38K | |
| 73630 | <1% | 2,769 | $36K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14,603 | $35K |
| 81025 | <1% | 13,801 | $35K | |
| 94060 | <1% | 878 | $33K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,144 | $33K |
| 82962 | <1% | 44,720 | $31K | |
| 73610 | <1% | 2,151 | $31K | |
| 85379 | <1% | 8,374 | $31K | |
| 97163 | <1% | 1,133 | $30K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,065 | $30K |
| 73130 | <1% | 1,869 | $30K | |
| 80069 | <1% | 22,625 | $29K | |
| 80076 | <1% | 10,491 | $29K | |
| 10060 | <1% | 412 | $27K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 488 | $27K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,181 | $27K |
| 92610 | <1% | 1,113 | $27K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 474 | $27K |
| 87186 | <1% | 8,793 | $26K | |
| 74022 | <1% | 1,386 | $26K | |
| 73030 | <1% | 2,140 | $25K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,272 | $24K |
| 0250 | <1% | 1,496 | $24K | |
| 72100 | <1% | 1,871 | $24K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 4,103 | $23K |
| 80074 | <1% | 2,592 | $23K | |
| 84145 | <1% | 3,912 | $22K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,162 | $22K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 5,804 | $22K |
| 93880 | <1% | 324 | $21K | |
| 94729 | <1% | 858 | $21K | |
| 82803 | <1% | 4,415 | $21K | |
| 47563 | <1% | 14 | $20K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 643 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 44,021 | $20K |
| 73110 | <1% | 1,068 | $20K | |
| 97165 | <1% | 810 | $19K | |
| 85027 | <1% | 9,133 | $19K | |
| Z7502 | <1% | 521 | $19K | |
| J2358 | Injection, olanzapine, long-acting, 1 mg | <1% | 1,104 | $19K |
| 70491 | <1% | 121 | $19K | |
| 0762 | <1% | 18 | $19K | |
| 80061 | Lipid panel | <1% | 4,571 | $18K |
| 0270 | <1% | 1,638 | $18K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 748 | $18K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 17,798 | $18K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 2,599 | $17K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 3,311 | $17K |
| 97167 | <1% | 542 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,692 | $17K |
| 97602 | <1% | 1,298 | $16K | |
| 73502 | <1% | 1,282 | $15K | |
| 82140 | <1% | 4,094 | $15K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 270 | $15K |
| 81003 | <1% | 18,212 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,387 | $13K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,003 | $13K |
| 74174 | <1% | 31 | $13K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,674 | $13K |
| 94726 | <1% | 481 | $12K | |
| C1781 | Mesh (implantable) | <1% | 145 | $12K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,675 | $12K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,582 | $12K |
| 94660 | <1% | 119 | $12K | |
| 87077 | <1% | 2,901 | $11K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 613 | $11K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 237 | $11K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,839 | $10K |
| 86140 | <1% | 6,856 | $10K | |
| 96368 | <1% | 1,226 | $9K | |
| J3490 | Unclassified drugs | <1% | 709 | $9K |
| 76775 | <1% | 656 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,225 | $9K |
| 74018 | <1% | 1,115 | $9K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,871 | $8K |
| 71101 | <1% | 513 | $8K | |
| 82607 | <1% | 2,339 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,888 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,781 | $8K |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 1,928 | $8K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 642 | $8K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,397 | $7K |
| 87070 | <1% | 3,900 | $7K | |
| 84439 | <1% | 5,478 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 11,478 | $6K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 5,336 | $6K |
| 36600 | <1% | 2,256 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 940 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,344 | $6K |
| 82330 | <1% | 1,564 | $6K | |
| 84481 | <1% | 3,711 | $6K | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 2,905 | $6K |
| 87205 | <1% | 5,361 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 7,501 | $6K |
| 73080 | <1% | 369 | $6K | |
| 73590 | <1% | 545 | $6K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,300 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 69 | $6K |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 1,187 | $5K |
| 72128 | <1% | 78 | $5K | |
| 99199 | Unlisted special service, procedure or report | <1% | 112 | $5K |
| 86901 | <1% | 6,428 | $5K | |
| 82010 | <1% | 1,811 | $5K | |
| 82746 | <1% | 1,699 | $5K | |
| 86900 | <1% | 6,257 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,072 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,017 | $5K |
| 11043 | <1% | 29 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 633 | $5K |
| 97597 | <1% | 716 | $5K | |
| 94664 | <1% | 704 | $5K | |
| 99070 | <1% | 610 | $5K | |
| 82728 | <1% | 2,282 | $4K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,127 | $4K |
| 73700 | <1% | 31 | $4K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 4,097 | $4K |
| 86850 | <1% | 5,209 | $4K | |
| 72040 | <1% | 339 | $4K | |
| 84132 | <1% | 3,731 | $4K | |
| 36430 | <1% | 327 | $4K | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 977 | $4K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 635 | $4K |
| 94644 | <1% | 235 | $4K | |
| 94727 | <1% | 291 | $4K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,529 | $4K |
| 84100 | <1% | 4,683 | $4K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 100 | $4K |
| 87486 | <1% | 571 | $3K | |
| 87581 | <1% | 571 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 692 | $3K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 563 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 231 | $3K |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 266 | $3K |
| 86923 | <1% | 469 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,548 | $3K |
| 80202 | <1% | 486 | $3K | |
| 87210 | <1% | 1,498 | $3K | |
| 86780 | <1% | 434 | $3K | |
| 83550 | <1% | 2,311 | $3K | |
| 85652 | <1% | 3,688 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 364 | $3K |
| 76870 | <1% | 92 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 112 | $2K |
| 87075 | <1% | 739 | $2K | |
| 83540 | <1% | 2,296 | $2K | |
| 91200 | <1% | 116 | $2K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 121 | $2K |
| 73090 | <1% | 152 | $2K | |
| 90686 | <1% | 690 | $2K | |
| 87563 | <1% | 125 | $2K | |
| 84295 | <1% | 1,559 | $2K | |
| 85014 | <1% | 3,081 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 404 | $1K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,424 | $1K |
| 82805 | <1% | 138 | $1K | |
| 64721 | <1% | 13 | $1K | |
| C1769 | Guide wire | <1% | 1,092 | $1K |
| 82570 | <1% | 1,660 | $1K | |
| 85046 | <1% | 1,427 | $1K | |
| 12001 | <1% | 42 | $1K | |
| 85018 | <1% | 3,135 | $1K | |
| Z7610 | <1% | 113 | $1K | |
| 76377 | <1% | 33 | $1K | |
| 29125 | <1% | 69 | $1K | |
| 87449 | <1% | 523 | $1K | |
| 72072 | <1% | 85 | $994.45 | |
| 87081 | <1% | 778 | $979.20 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 216 | $917.77 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,329 | $904.76 |
| 83615 | <1% | 897 | $856.61 | |
| P9046 | Infusion, albumin (human), 25%, 20 ml | <1% | 35 | $845.35 |
| 87276 | <1% | 380 | $817.12 | |
| 84300 | <1% | 1,449 | $791.99 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 55 | $784.02 |
| 83930 | <1% | 863 | $780.64 | |
| 87275 | <1% | 381 | $777.62 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 821 | $674.60 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 280 | $619.91 |
| 80164 | <1% | 232 | $600.20 | |
| 87184 | <1% | 328 | $581.22 | |
| 85520 | <1% | 124 | $579.54 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 996 | $517.16 |
| 87631 | <1% | 206 | $506.77 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 274 | $468.17 |
| 99152 | <1% | 58 | $457.78 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 70 | $409.44 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 1,160 | $327.77 |
| 72170 | <1% | 48 | $299.92 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 39 | $258.94 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 21 | $251.38 |
| 73140 | <1% | 14 | $227.73 | |
| 84550 | <1% | 168 | $223.70 | |
| 82947 | <1% | 107 | $217.34 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 355 | $217.14 |
| 82542 | <1% | 53 | $195.91 | |
| 83935 | <1% | 267 | $191.73 | |
| 73552 | <1% | 12 | $155.02 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 190 | $149.20 |
| 87899 | <1% | 205 | $148.15 | |
| 83970 | <1% | 19 | $118.55 | |
| 85384 | <1% | 184 | $110.01 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 21 | $107.23 |
| 84540 | <1% | 406 | $100.69 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 14 | $100.43 |
| A9270 | Non-covered item or service | <1% | 49,871 | $100.30 |
| 84156 | <1% | 157 | $92.50 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 98 | $87.97 |
| 84133 | <1% | 177 | $76.65 | |
| 82248 | <1% | 53 | $72.63 | |
| 82436 | <1% | 154 | $68.86 | |
| 87430 | <1% | 76 | $68.31 | |
| 82565 | <1% | 29 | $64.29 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 930 | $57.79 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 28 | $34.85 |
| 83010 | <1% | 38 | $34.32 | |
| 84155 | <1% | 16 | $23.28 | |
| 84520 | <1% | 14 | $21.60 | |
| 83520 | <1% | 20 | $17.66 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 106 | $11.03 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | <1% | 12 | $9.38 |
| 89051 | <1% | 17 | $7.52 | |
| 87181 | <1% | 15 | $7.02 | |
| 85007 | <1% | 102 | $2.59 | |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 100 | $0.01 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 58 | $0.01 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | <1% | 57 | $0.01 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 403 | $0.01 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 403 | $0.01 |
| C1729 | Catheter, drainage | 0% | 45 | $0.00 |
| 0353U | 0% | 712 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 432 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 435 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 295 | $0.00 |
| 88312 | 0% | 39 | $0.00 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 33 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 51 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 13 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.